MMR II

Live measles, mumps & rubella virus vaccine

Active immunization against measles, mumps & rubella in individuals ≥12 mth.

SC 0.5 mL/dose. Administer 1st dose at 12-15 mth of age; administer 2nd dose at 4-6 yr of age. Post-exposure prophylaxis of measles 1 dose w/in 72 hr after exposure.

Hypersensitivity to any component of the vaccine, including gelatin. Hypersensitivity reaction following administration of a previous dose of MMR II vaccine or any other measles, mumps & rubella-containing vaccine. History of anaphylaxis to neomycin. Individuals who are immunodeficient or immunosuppressed due to disease or medical therapy. Febrile illness w/ fever >101.3°F (>38.5°C). Active untreated TB. Pregnancy. Women planning on becoming pregnant w/in the next mth.

Risk of fever & associated febrile seizures in the 1st 2 wk following immunization. Individuals w/ history of anaphylactic, anaphylactoid, or other immediate reactions subsequent to egg ingestion may be at an enhanced risk of immediate-type hypersensitivity reactions after vaccination. Transient thrombocytopenia w/in 4-6 wk following vaccination. Defer vaccination in individuals w/ family history of congenital or hereditary immunodeficiency until immunocompetence is confirmed. Do not give concurrently w/ Ig & other blood products. Lactation. Not approved for individuals <12 mth of age.

Panniculitis, atypical measles, fever, syncope, headache, dizziness, malaise, irritability; vasculitis; pancreatitis, diarrhea, vomiting, parotitis, nausea; thrombocytopenia, purpura, regional lymphadenopathy, leukocytosis; anaphylaxis & anaphylactoid reactions, angioedema, bronchial spasm; arthritis, arthralgia, myalgia; encephalitis, encephalopathy, measles inclusion body encephalitis (MIBE), subacute sclerosing panencephalitis (SSPE), Guillain-Barré syndrome (GBS), acute disseminated encephalomyelitis (ADEM); transverse myelitis, febrile convulsions, afebrile convulsions or seizures, ataxia, polyneuritis, polyneuropathy, ocular palsies, paresthesia; pneumonia, pneumonitis, sore throat, cough, rhinitis; Stevens-Johnson syndrome, acute hemorrhagic edema of infancy, Henoch-Schönlein purpura, erythema multiforme, urticaria, rash, measles-like rash, pruritus, inj site reactions; nerve deafness, otitis media; retinitis, optic neuritis, papillitis, conjunctivitis; epididymitis, orchitis.

Risk of disseminated disease due to measles vaccine in individuals on immunosuppressive drugs. Possible interference w/ expected immune response if concurrently administered w/ Ig & other blood products. May result in a temporary depression of tuberculin skin sensitivity. If a tuberculin skin test w/ tuberculin purified protein derivative (PPD) is to be done, administer before, simultaneously w/, or at least 4-6 wk after vaccination w/ MMR II vaccine. Can be administered concurrently w/ other live viral vaccines. If not given concurrently, MMR II vaccine should be given 1 mth before or 1 mth after administration of other live viral vaccines to avoid potential for immune interference.

Vaccines, Antisera & Immunologicals

J07BD52 - measles, combinations with mumps and rubella, live attenuated ; Belongs to the class of morbilli viral vaccines.

P₁S₁S₃, A